TherapeuticsMD (TXMD) Downgraded by Zacks Investment Research to Sell

TherapeuticsMD (NASDAQ:TXMD) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research report issued on Friday.

According to Zacks, “TherapeuticsMD, Inc. is a specialty pharmaceutical company focused on creating branded prescription, generic prescription and over-the-counter products targeted exclusively for women. It is developing three advanced hormone replacement products designed to alleviate the symptoms of and reduce the health risks resulting from menopause-related hormone deficiencies. TherapeuticsMD, Inc. is based in Boca Raton, Florida. “

Other equities research analysts have also issued research reports about the stock. Noble Financial reissued a “buy” rating on shares of TherapeuticsMD in a report on Wednesday, December 20th. Oppenheimer set a $10.00 price target on shares of TherapeuticsMD and gave the stock a “buy” rating in a report on Wednesday, December 20th. Deutsche Bank set a $9.00 price target on shares of TherapeuticsMD and gave the stock a “buy” rating in a report on Wednesday, December 20th. Cantor Fitzgerald reissued a “buy” rating and issued a $31.00 price target on shares of TherapeuticsMD in a report on Wednesday, November 29th. Finally, Jefferies Group reissued a “buy” rating and issued a $15.00 price target on shares of TherapeuticsMD in a report on Tuesday, September 26th. Two investment analysts have rated the stock with a sell rating, one has issued a hold rating and eight have assigned a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus price target of $14.50.

TherapeuticsMD (NASDAQ:TXMD) traded down $0.09 on Friday, hitting $6.15. 1,297,951 shares of the company traded hands, compared to its average volume of 1,627,289. TherapeuticsMD has a 1 year low of $3.50 and a 1 year high of $8.30. The firm has a market cap of $1,330.00, a PE ratio of -15.77 and a beta of 1.06.

TherapeuticsMD (NASDAQ:TXMD) last posted its earnings results on Monday, November 6th. The company reported ($0.07) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.10) by $0.03. The firm had revenue of $4.42 million during the quarter, compared to analysts’ expectations of $5.36 million. TherapeuticsMD had a negative net margin of 457.00% and a negative return on equity of 65.16%. The business’s revenue was down 19.7% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.13) EPS. sell-side analysts forecast that TherapeuticsMD will post -0.37 earnings per share for the current year.

In other TherapeuticsMD news, Director Tommy G. Thompson bought 5,000 shares of the company’s stock in a transaction dated Friday, December 8th. The stock was acquired at an average price of $6.21 per share, with a total value of $31,050.00. Following the completion of the acquisition, the director now directly owns 3,555 shares of the company’s stock, valued at $22,076.55. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 23.92% of the stock is owned by corporate insiders.

Institutional investors have recently added to or reduced their stakes in the company. Candriam Luxembourg S.C.A. grew its holdings in shares of TherapeuticsMD by 10.4% during the third quarter. Candriam Luxembourg S.C.A. now owns 530,000 shares of the company’s stock worth $2,804,000 after buying an additional 50,000 shares in the last quarter. Schwab Charles Investment Management Inc. grew its holdings in shares of TherapeuticsMD by 10.8% during the second quarter. Schwab Charles Investment Management Inc. now owns 694,167 shares of the company’s stock worth $3,659,000 after buying an additional 67,855 shares in the last quarter. Raymond James Financial Services Advisors Inc. grew its holdings in shares of TherapeuticsMD by 26.6% during the third quarter. Raymond James Financial Services Advisors Inc. now owns 142,930 shares of the company’s stock worth $756,000 after buying an additional 30,030 shares in the last quarter. Swiss National Bank grew its holdings in shares of TherapeuticsMD by 12.3% during the third quarter. Swiss National Bank now owns 289,800 shares of the company’s stock worth $1,533,000 after buying an additional 31,800 shares in the last quarter. Finally, Stifel Financial Corp grew its holdings in shares of TherapeuticsMD by 377.9% during the second quarter. Stifel Financial Corp now owns 2,052,030 shares of the company’s stock worth $10,820,000 after buying an additional 1,622,668 shares in the last quarter. 73.69% of the stock is owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION NOTICE: “TherapeuticsMD (TXMD) Downgraded by Zacks Investment Research to Sell” was originally reported by American Banking News and is owned by of American Banking News. If you are viewing this piece on another site, it was copied illegally and republished in violation of United States and international trademark and copyright laws. The correct version of this piece can be viewed at https://www.americanbankingnews.com/2018/01/12/therapeuticsmd-txmd-downgraded-by-zacks-investment-research-to-sell.html.

About TherapeuticsMD

TherapeuticsMD, Inc is a women’s healthcare company engaged in creating and commercializing products for women. The Company is focused on pursuing regulatory approvals and pre-commercialization activities necessary for commercialization of its hormone therapy pharmaceutical products. Its drug candidates used in clinical trials are designed to alleviate symptoms of and reduce health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis and vaginal discomfort.

Get a free copy of the Zacks research report on TherapeuticsMD (TXMD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for TherapeuticsMD (NASDAQ:TXMD)

Receive News & Ratings for TherapeuticsMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply